cTRL Therapeutics

cTRL Therapeutics is a United States cell therapy company based in Chicago, Illinois. The company is developing a first-of-its-kind polyclonal cell therapy intended to treat solid tumors, which it notes represent roughly 90% of all cancers. Its approach centers on cTRLs — described by the company as a rare and potent circulating T cell population found in the blood that is naturally equipped to fight cancer. Rather than relying on surgically removed tumor tissue, as tumor-infiltrating lymphocyte (TIL) therapies do, cTRL Therapeutics aims to derive its therapeutic cells from a single blood draw. The company's proprietary IsoQore™ cell-sorting platform is designed to isolate and extract millions of cTRLs from the bloodstream by identifying migratory, tumor-reactive cells via novel markers. cTRL Therapeutics positions this platform as a way to simplify the complexities of solid tumor cell therapy development, manufacturing and administration, and to eliminate the need for invasive surgery to obtain tumor tissue. The company presents itself as a team of cell therapy pioneers applying decades of experience to fundamental challenges that have historically stymied progress against solid tumors. cTRL Therapeutics operates in the biotechnology and life sciences sector, with a focus on oncology cell therapy. Its public communications emphasize solid tumor treatments, the limitations of existing approaches such as TILs and TCR-based therapies, and the potential of cTRL-based therapy to broaden the reach of curative cell therapy beyond blood cancers. The company is privately held and recruits through its website under the banner of redefining control over solid tumors.

cTRL Therapeutics is a privately held cell therapy company located in Chicago, Illinois, United States. Public information about the company is primarily available through its official website, which describes its scientific approach and platform. The company's founding year, founders and ownership structure are not specified in the available evidence. The company's core premise is that cTRLs — a rare and potent circulating T cell population found in the blood and naturally equipped to fight cancer — can be harnessed to engineer solid tumor cell therapies. cTRL Therapeutics notes that solid tumors have yet to benefit from the curative cell therapy breakthroughs seen in blood cancers. It contrasts its approach with emerging treatments such as TILs, which it says utilize exhausted cells from surgically removed cancer tissue in an invasive and complex process for patients, and with TCR-based therapies, which it says lack a breadth of tumor-specific targets. To address these limitations, cTRL Therapeutics is developing a first-of-its-kind polyclonal cell therapy to treat solid tumors without the need to surgically remove tumor tissue. The company states that from a single blood draw it can obtain sufficient quantities of rare polyclonal cTRLs against solid tumors. It has developed a proprietary cell-sorting platform called IsoQore™ that identifies migratory, tumor-reactive cells in the bloodstream via novel markers, enabling the efficient isolation and extraction of millions of cTRLs. cTRL Therapeutics positions its cTRL-based therapy as having the potential to eliminate the challenges of invasive surgery and to simplify the complexities of solid tumor cell therapy development, manufacturing and administration. The company describes itself as experts in cell therapy discovery and development applying decades of experience to the fundamental challenges that have stymied progress against solid tumors, and it invites visitors to meet its team of cell therapy pioneers and explore careers.

Developer of a first-of-its-kind polyclonal cell therapy for solid tumors, using a proprietary IsoQore™ platform to isolate cTRLs from a single blood draw.

• Polyclonal cTRL-based cell therapy for solid tumors

  A first-of-its-kind polyclonal cell therapy in development to treat solid tumors without the need to surgically remove tumor tissue, derived from cTRLs obtained via a single blood draw.

• IsoQore™

  A proprietary cell-sorting platform that identifies migratory, tumor-reactive cells in the bloodstream via novel markers, enabling efficient isolation and extraction of millions of cTRLs.

1. 1cTRL Txctrl-tx.com
2. 2cTRL Therapeutics (United States) - Wikidatawikidata.org